scholarly journals Supplementation of Optimum Nutrient-Dense Formula to Modulate HIV Infection in Resource Limited Settings

2019 ◽  
Vol 5 (1) ◽  
pp. 73-75
Author(s):  
Abraham Mainaji Amlogu
2020 ◽  
Vol 7 (11) ◽  
pp. 1747
Author(s):  
Dnyanesh N. Morkar ◽  
Ankita Aneja ◽  
Rishabh Agarwal

The prognosis of HIV infection has considerably improved following the introduction of highly active anti-retroviral therapy by reducing AIDS related morbidity and mortality. At the same time, ART drugs are well known for their side effects. Gynaecomastia is a lesser known side effect of a commonly used anti-retroviral drug efavirenz. There are very few reports of HAART-induced gynaecomastia in resource-limited settings. The current study presents a series of three cases that developed ultrasound confirmed gynaecomastia following efavirenz containing HAART. Initial reports of gynaecomastia related to HAART were in HIV patients with lipodystrophy, they were termed as pseudogynaecomastia. Gradually, few reports of efavirenz related gynaecomastia were published wherein other causes of gynaecomastia were ruled out. Several hypothesis have been suggested for the pathophysiology of development of gynaecomastia related to efavirenz consumption. All other causes were ruled out in our patients too. The incidence of gynaecomastia is increasing in men with HIV on HAART therapy, proper identification and management will promote better drug adherence.


2009 ◽  
Vol 6 (4) ◽  
pp. 217-223 ◽  
Author(s):  
Ishani Ganguli ◽  
Ingrid V. Bassett ◽  
Krista L. Dong ◽  
Rochelle P. Walensky

2017 ◽  
Vol 33 (2) ◽  
pp. 50-53
Author(s):  
Wentzel Dowling ◽  
Kirsten Veldsman ◽  
Mary Grace Katusiime ◽  
Jean Maritz ◽  
Peter Bock ◽  
...  

2007 ◽  
Vol 53 (5) ◽  
pp. 355-358 ◽  
Author(s):  
S. Sivapalasingam ◽  
U. Patel ◽  
V. Itri ◽  
M. Laverty ◽  
K. Mandaliya ◽  
...  

2021 ◽  
Vol 8 (7) ◽  
pp. 984
Author(s):  
Balakrishna Teli ◽  
Sneha Biradar ◽  
Sheshan V. S.

The prognosis of HIV infection has significantly changed following the introduction of highly active anti-retroviral therapy by reducing AIDS related morbidity and mortality. At the same time, HAART is documented for its side effects. Gynaecomastia is a less documented side effect of a commonly used ART drug efavirenz. There are only few case reports of HAART-induced gynaecomastia in resource limited settings. Initially gynaecomastia related to HAART in HIV patients was thought due to lipodystrophy and was termed as pseudogynaecomastia. Later, few case reports of efavirenz related gynaecomastia were published after ruling out other causes of gynaecomastia. All other causes of gynaecomastia were ruled out in our patients too. The incidence of gynaecomastia is increasing in men with HIV on HAART therapy, proper identification and management will promote better drug adherence. The present study presented a series of two cases that developed ultrasound confirmed gynaecomastia following efavirenz containing HAART.


2015 ◽  
Vol 89 (21) ◽  
pp. 10868-10878 ◽  
Author(s):  
Angela Wahl ◽  
Caroline Baker ◽  
Rae Ann Spagnuolo ◽  
Lisa W. Stamper ◽  
Genevieve G. Fouda ◽  
...  

ABSTRACTDespite the nutritional and health benefits of breast milk, breast milk can serve as a vector for mother-to-child HIV transmission. Most HIV-infected infants acquire HIV through breastfeeding. Paradoxically, most infants breastfed by HIV-positive women do not become infected. This is potentially attributed to anti-HIV factors in breast milk. Breast milk of HIV-negative women can inhibit HIV infection. However, the HIV-inhibitory activity of breast milk from HIV-positive mothers has not been evaluated. In addition, while significant differences in breast milk composition between transmitting and nontransmitting HIV-positive mothers have been correlated with transmission risk, the HIV-inhibitory activity of their breast milk has not been compared. This knowledge may significantly impact the design of prevention approaches in resource-limited settings that do not deny infants of HIV-positive women the health benefits of breast milk. Here, we utilized bone marrow/liver/thymus humanized mice to evaluate thein vivoHIV-inhibitory activity of breast milk obtained from HIV-positive transmitting and nontransmitting mothers. We also assessed the species specificity and biochemical characteristics of milk'sin vivoHIV-inhibitory activity and its ability to inhibit other modes of HIV infection. Our results demonstrate that breast milk of HIV-positive mothers has potent HIV-inhibitory activity and indicate that breast milk can prevent multiple routes of infection. Most importantly, this activity is unique to human milk. Our results also suggest multiple factors in breast milk may contribute to its HIV-inhibitory activity. Collectively, our results support current recommendations that HIV-positive mothers in resource-limited settings exclusively breastfeed in combination with antiretroviral therapy.IMPORTANCEApproximately 240,000 children become infected with HIV annually, the majority via breastfeeding. Despite daily exposure to virus in breast milk, most infants breastfed by HIV-positive women do not acquire HIV. The low risk of breastfeeding-associated HIV transmission is likely due to antiviral factors in breast milk. It is well documented that breast milk of HIV-negative women can inhibit HIV infection. Here, we demonstrate, for the first time, that breast milk of HIV-positive mothers (nontransmitters and transmitters) inhibits HIV transmission. We also demonstrate that breast milk can prevent multiple routes of HIV acquisition and that this activity is unique to human milk. Collectively, our results support current guidelines which recommend that HIV-positive women in resource-limited settings exclusively breastfeed in combination with infant or maternal antiretroviral therapy.


2008 ◽  
Vol 7 (3) ◽  
pp. 283-293 ◽  
Author(s):  
Alain Makinson ◽  
Vincent Le Moing ◽  
Charles Kouanfack ◽  
Christian Laurent ◽  
Eric Delaporte

Sign in / Sign up

Export Citation Format

Share Document